18 September 2026
Aspen's turnaround hinges on filling its underused sterile manufacturing plants, as GLP-1 sales drive a share recovery.
8 September 2026
Aspen Pharmacare earnings rose 22% as demand for Eli Lilly's weight-loss drug Mounjaro surged, with the group also eyeing generic semaglutide.
7 March 2026
Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
9 February 2026
3 February 2026
Roche CT-388 Obesity Drug shows up to 22.5% placebo-adjusted weight loss at 48 weeks, as Roche moves into Phase 3 to challenge Lilly and Novo.
14 January 2026
Aspen APAC divestment unlocks R26.5bn in capital, sharpening the group’s focus on GLP-1 injectables and reducing net debt heading into 2026.
14 January 2026
GLP-1 weight loss drugs like Mounjaro and Wegovy are transforming obesity treatment in SA amid rising health concerns and systemic barriers.
24 November 2025
Eli Lilly hits $1 trillion valuation, marking a historic milestone in the pharmaceutical industry with successful weight-loss drugs.
5 November 2025
Aspen's Mounjaro expansion plans promise to enhance diabetes and weight management treatment in Sub-Saharan Africa soon.
15 October 2025
Aspen shares soar following the approval of Mounjaro for weight loss in South Africa. Discover the impact on obesity management.
11 September 2025
4 September 2025
Understand Aspen Unlocking Value efforts as CEO Stephen Saad addresses the decline in share price and targets business improvements.